Forte Biosciences, Inc.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. Its lead product candidate is FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic. FB-102 is being investigated for indications such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company is headquartered in Dallas, Texas, and operates within the biotechnology industry.

Forte Biosciences, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol FBRX. The trading currency is the US Dollar (USD). As a US-based company, its stock is traded in USD, which is standard for companies listed on US exchanges.

Forte Biosciences operates in the Healthcare sector and specifically within the Biotechnology industry. Biotechnology companies like Forte focus on using biological processes to develop drugs and therapies. The company's work in developing monoclonal antibodies for autoimmune diseases places it firmly in the biotech space, which involves extensive research and clinical trials.

Forte Biosciences, Inc. is headquartered in Dallas, Texas, United States. As a clinical-stage biopharmaceutical company, it primarily serves the US market, where it conducts its research and development activities. The company's focus on autoimmune diseases targets a global patient population, but its operations and regulatory efforts are centered in the United States.